




MDH-011 for the Treatment of Intractable Respiratory Disease

MDH-011 (*Lactobacillus paracasei* EV) is a new class of first-in-class oral therapeutic indicated for intractable respiratory diseases, such as idiopathic pulmonary fibrosis (IPF), viral & nosocomial pneumonia, and more

MDH-011

- Naïve (natural) EVs from a single **Lactobacillus** strain



Value Propositions

1. **First-in-class**: a new modality drug with a novel mechanism of action (MoA)
2. **Very safe**: a newly discovered and safe commensal bacterium *Lactobacillus paracasei*-derived EVs
3. **Effective**: a disease-modifying therapy against intractable respiratory diseases, including idiopathic pulmonary fibrosis (IPF) & pneumonia
4. **Convenient administration**: orally-delivered
5. **Affordable**: cost effective production

MDH-011: Key Indications & Development Timeline

Key Indications

- 1) Idiopathic pulmonary fibrosis (IPF)
- 2) Viral pneumonia
- 3) Nosocomial pneumonia
- 4) Interstitial pneumonitis

Core patent

- ✓ KR (10-2021-0014070) application date at 08/Dec/2021
- ✓ PCT (KR2021/018664) application date at 09/Dec/2021
- ✓ Pending at US (as of July 2022)

Development Timeline

IND filing ('22)



P1 ('23)



P2 ('25)



Exit